Table 3.
Best response and DCR of systemic therapies with PRRT and SSA in mPGGLs
| First-line PRRT | Second-line PRRT | First-line SSA | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PR | SD | PD | NA | DCR | PR | SD | PD | NA | DCR | PR | SD | PD | NA | DCR | |
| Mutation | |||||||||||||||
| SDHA | — | — | — | — | — | — | — | — | — | — | — | 1 | — | — | 100% |
| SDHB | 2 | 5 | 3 (1) | — | 70% | — | 1 (1) | 1 | — | 50% | — | 1 | — | 100% | |
| SDHD | — | 1 (1) | — | — | 100% | — | — | — | — | — | — | 1 | — | — | 100% |
| HRAS | — | — | 1 | — | 0% | — | — | — | — | — | — | 1 (1) | — | 100% | |
| RET | 1 | — | 1 | — | 50% | — | — | — | — | — | — | — | — | — | — |
| No mutation | — | 4 | 1 (1) | 1 (1) | 80% | — | 1 | 1 | — | 50% | — | 2 | — | — | 100% |
| NA | — | 1 | 1 | — | 50% | — | 1 | — | — | 100% | — | — | — | — | — |
| Total | 3 | 11 | 7 | 1 | 67% | — | 3 | 2 | — | 60% | — | 6 | — | — | 100% |
In brackets: number of SSTR2 IHC stained tumors (all stained tumors were SSTR2 IHC positive).
Abbreviations: DCR, disease control rate; NA, not available; PD, progressive disease; PR, partial response; PRRT, somatostatin peptide receptor–based radionuclide therapy; SSA, “cold” somatostatin analog; SD, stable disease.